C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00688454

Enrollment

3392

Registered

2008-06-03

Start date

2007-02-28

Completion date

2008-01-31

Last updated

2009-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesteremia

Keywords

Hyperlipidemia, Rosuvastatin, Efficacy, tolerability, CRESTOR therapy

Brief summary

The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with hypercholesteremia who was never treated with statins before * Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin	3 visits within 10 weeks

Secondary

Measure	Time frame
Tolerability of CRESTOR-therapy	3 visits within 10 weeks

Outcome results